Introduction
Thrombotic microangiopathy (TMA) is a wellrecognized complication of solid organ transplantation. Both calcineurin inhibitors cyclosporine [1] and tacrolimus [2] have been associated with TMA. Treatment strategies for TMA have included plasmapheresis [1, 2] , calcineurin inhibitor dose reduction [1, 2] , calcineurin inhibitor withdrawal [1, 2] , and conversion from one calcineurin inhibitor to the other [3] . However, calcineurin inhibitor dose reduction or discontinuation increases the risk of acute allograft rejection and recurrent TMA has been described in patients that were converted from cyclosporine to tacrolimus [4, 5] . We present two cases of biopsy-proven transplant-associated TMA that were successfully treated by discontinuation of tacrolimus followed by the use of sirolimus, mycophenolate mofetil (MMF) and prednisone for the prevention of allograft rejection.
Case 1
A 42-year-old white male with end-stage renal disease due to type I diabetes mellitus received a cadaveric renal transplant in June 2000. Both donor and recipient were sero-negative for cytomegalovirus. Initial immunosuppression consisted of thymoglobulin 100 mguday and methylprednisolone. The allograft functioned immediately and on post-operative day 1 the serum creatinine had fallen from 597 to 247 mmolul and the platelet count was 259 000umm 3 . On postoperative day 6, the serum creatinine reached a nadir of 103 mmolul and tacrolimus was started at a dose of 5 mg p.o. twice a day (BID). On post-operative day 8, the serum creatinine increased to 140 mmolul, the platelet count was 182 000umm 3 , and the tacrolimus level was 5.7 nguml. The following day, the serum creatinine increased to 282 mmolul, the platelet count was 219 000umm 3 , and a renal biopsy was performed. The biopsy revealed multiple thrombi in the glomerular capillaries without any interstitial lymphoid infiltrate, tubulitis, or endothelitis, confirming the diagnosis of TMA. The tacrolimus was discontinued and the patient continued to receive thymoglobulin and methylprednisolone. Plasmapheresis was initiated and continued for a total of seven treatments. On postoperative day 10, the serum creatinine peaked at 359 mmolul and then began to decline. During this period, the platelet count fell to a nadir of 93 000umm 3 on post-operative day 13. The platelet count returned to within the reference range 4 days later, where it has remained to the present.
On post-operative day 19, the serum creatinine was 131 mmolul. Sirolimus was started at a dose of 8 mguday and the dose was adjusted to maintain levels between 5 and 15 nguml. MMF was also started at 2000 mguday. The patient has had no complications with this immunosuppressive regimen and remains rejectionfree. The TMA has not recurred. At the last follow-up (19 months post-transplant) the serum creatinine was 104 mmolul, the platelet count was 301 000umm 3 , and the sirolimus level was 6.7 nguml. Current immunosuppression consists of sirolimus 4 mguday, MMF 1000 mguday, and prednisone 7.5 mguday. creatinine fell from 666 to 184 mmolul by the third post-operative day. The following day, the serum creatinine increased to 220 mmolul, the tacrolimus level was 9.1 nguml, and the platelet count was 151 000umm 3 . The tacrolimus was discontinued, MMF was decreased to 750 mg BID, and thymoglobulin 75 mguday was started for what was suspected to be accelerated acute rejection. On post-operative day 7, the serum creatinine was 123 mmolul and tacrolimus was resumed at 5 mg p.o. BID. The platelet count remained within the reference range throughout this period. Three days later the urine output decreased abruptly, the serum creatinine increased to 347 mmolul, the tacrolimus level was 8.9 nguml, and the platelet count was 124 000umm 3 . A renal biopsy was performed which revealed fibrin thrombi in the glomerular capillaries. There was a small focus of neutrophils in the interstitium but there was no lymphocytic infiltrate, tubulitis, or vasculitis. The biopsy confirmed the diagnosis of TMA and the tacrolimus was discontinued. Sirolimus was started at 5 mguday and the MMF was decreased to 500 mg BID. Plasmapheresis was started and continued for 6 days.
Case 2
On post-operative day 11, the platelet count fell to 114 000umm 3 and reached a nadir of 52 000umm 3 4 days later. Over the next few days the platelet count improved but the serum creatinine continued to rise reaching 581 mmolul on post-operative day 20. A second renal biopsy was performed which revealed acute tubular necrosis; there was no evidence of rejection and the characteristic features of TMA had completely resolved. Over the next 2 weeks the renal function steadily improved and on post-operative day 48 the serum creatinine was 125 mmolul and the platelet count was 158 000umm 3 . The TMA has not recurred and the patient remains rejection-free with excellent allograft function. At the last follow-up (12 months post-transplant), the serum creatinine was 108 mmolul, the platelet count was 245 000umm 3 , and the sirolimus level was 8.9 nguml. Current immunosuppression consists of sirolimus 8 mguday, MMF 1000 mguday, and prednisone 7.5 mguday.
Discussion
Most reports of transplant-associated TMA have recommended a dose reduction or complete withdrawal of calcineurin inhibitors [1, 2] . Although this manoeuvre often leads to resolution of the TMA, the risk of allograft rejection is increased, especially in the early post-transplant period. To reduce the risk of acute rejection others have recommended switching from one calcineurin inhibitor to the other [3] . However, this treatment option is not without risk as recurrent TMA has been reported after a change from cyclosporine to tacrolimus, culminating in graft loss in one report [4, 5] . Although they have different immunophilin binding proteins, cyclosporine and tacrolimus have similar mechanisms of immunosuppressive action and common toxicities [6] . Both drugs have similar effects on the vasculature leading to vasoconstriction, increased endothelin levels, increased thromboxane A 2 , and decreased nitric oxide production [7] . These vascular changes have been associated with the endothelial cell injury that is central to the pathogenesis of TMA [7] . As cyclosporine and tacrolimus both have the potential to damage endothelial cells the rationale for converting from one drug to the other during an episode of TMA is not well founded.
Sirolimus is a macrocyclic lactone that has an immunosuppressive mechanism of action and sideeffect profile that is distinct from cyclosporine and tacrolimus [6, 8] . Sirolimus does not lead to vasoconstriction or nephrotoxicity, features common to the calcineurin inhibitors [8] . In an animal study, sirolimus had an opposite effect on the microvasculature compared with cyclosporine [9] . Sirolimus use resulted in high local nitric oxide levels with minimal intimal hyperplasia whereas cyclosporine led to significant intimal hyperplasia and no inducible nitric oxide expression [9] . The data may suggest that sirolimus has less potential for endothelial toxicity than calcineurin inhibitors.
The combination of sirolimus, MMF, and corticosteroids has been compared with a cyclosporine-based regimen with comparable results in terms of biopsyproven acute rejection, patient survival, and renal allograft survival [10] . In addition, the glomerular filtration rate was significantly higher in the sirolimustreated group compared with the patients receiving cyclosporine [10] . Thus, the combination of sirolimus, MMF, and corticosteroids appears to be an effective alternative to cyclosporine-based immunosuppression for the prevention of renal allograft rejection.
The cases presented herein are typical of transplantassociated TMA, in that thrombocytopenia and other clinical features of TMA were mild or absent at the time of diagnosis, despite a severe deterioration in allograft function [11] . In both instances the diagnosis of TMA was not suspected and required a renal biopsy. We have reported an alternative and rational approach to the management of transplant-associated TMA. Rather than reducing the dose of calcineurin inhibitor or switching from one calcineurin inhibitor to the other, we have demonstrated that sirolimus can replace the calcineurin inhibitor, allowing for complete resolution of the TMA. This did not occur at the expense of acute rejection, and to date both subjects enjoy excellent allograft function. A calcineurin inhibitor-free regimen of sirolimus, MMF and prednisone has the advantage of reducing the risk of recurrent TMA while providing adequate prophylaxis from acute rejection.
